Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_assertion type Assertion NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_head.
- NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_assertion description "[A combined ELISA for both LY6K and CEA classified 64.7% of lung adenocarcinoma patients as positive, and the use of both LY6K and CYFRA 21-1 increased sensitivity in the detection of lung squamous cell carcinomas and ESCCs up to 70.4% and 52.5%, respectively, whereas the false positive rate was 6.8% to 9.5%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_provenance.
- NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_assertion evidence source_evidence_literature NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_provenance.
- NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_assertion SIO_000772 18089789 NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_provenance.
- NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_assertion wasDerivedFrom befree-20150227 NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_provenance.
- NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_assertion wasGeneratedBy ECO_0000203 NP913713.RAKlBx2qadSqKIdyF6VW9HUo7bKVpbTplvtioCDznUkxU130_provenance.